Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RHHBY Roche Holding Ltd

Market Closed 05-17 16:00:00 EDT Delay

盘后32.85

+0.04+0.12%

16:04 EDT

{"stockData":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":32.81,"timestamp":1715976000000,"preClose":32.65,"halted":0,"volume":2780141,"hourTrading":{"tag":"盘后","latestPrice":32.85,"preClose":32.81,"latestTime":"16:04 EDT","volume":10378,"amount":341138.79899999994,"timestamp":1715976281355},"delay":15,"floatShares":5819810072,"shares":6377935560,"eps":1.550894,"marketStatus":"Market Closed","change":0.16,"latestTime":"05-17 16:00:00 EDT Delay","open":32.56,"high":32.99,"low":32.44,"amount":90977838.27098012,"amplitude":0.016845,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":32.65,"volumeRatio":0.8725872538290985},"requestUrl":"/m/hq/s/RHHBY","defaultTab":"news","newsList":[{"id":"2436918085","title":"Novo Nordisk, J&J lead R&D rankings in big pharma: report","url":"https://stock-news.laohu8.com/highlight/detail?id=2436918085","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436918085?lang=en_us&edition=fundamental","pubTime":"2024-05-19 02:52","pubTimestamp":1716058327,"startTime":"0","endTime":"0","summary":"Weight loss drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) have become the most transformative companies in big pharma, according to a new report bas","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1461608537/image_1461608537.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1461608537/image_1461608537.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma","is_publish_highlight":false,"gpt_icon":0},{"id":"2436189468","title":"Roche Is Joining The Obesity Party But Questions Remain","url":"https://stock-news.laohu8.com/highlight/detail?id=2436189468","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436189468?lang=en_us&edition=fundamental","pubTime":"2024-05-18 23:18","pubTimestamp":1716045533,"startTime":"0","endTime":"0","summary":"Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24.The full data presentation is needed to assess safety and tolerabili","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694321-roche-is-joining-the-obesity-party-but-questions-remain","is_publish_highlight":false,"gpt_icon":0},{"id":"2436902826","title":"Bet Against the Crowd: 3 Stocks Set to Surge Against All Odds","url":"https://stock-news.laohu8.com/highlight/detail?id=2436902826","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2436902826?lang=en_us&edition=fundamental","pubTime":"2024-05-18 19:00","pubTimestamp":1716030000,"startTime":"0","endTime":"0","summary":"These stocks hold a contrarian perspective, offering a chance to capitalize on undervalued assets.Alibaba : The firm has been achieving top-line diversification and international expansion, driving a solid increase in AIDC revenue.Paramount : The entertainment giant delivered high revenue growth in its D2C segment, with Paramount+ subscribers exceeding 71 million.Intel : The semiconductor company is leading with technological advancements with the 14A process node and expects the production ramp of the 20A in H2 2024.Moreover, the second one has solid growth in its direct-to-consumer  sector. This marksa sharp rise in revenue and a steadily expanding subscriber base.Thisalso indicates the company’s edge in shifting consumers’ preferences. The company may attain long-term growth and has established a solid lead in the streaming sector.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/bet-against-the-crowd-3-stocks-set-to-surge-against-all-odds/","is_publish_highlight":false,"gpt_icon":0},{"id":"2436940410","title":"Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race","url":"https://stock-news.laohu8.com/highlight/detail?id=2436940410","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436940410?lang=en_us&edition=fundamental","pubTime":"2024-05-18 02:15","pubTimestamp":1715969751,"startTime":"0","endTime":"0","summary":"Roche's acquisition of Carmot Therapeutics and their obesity drug CT-388 showed promising Phase 1b results, boosting Roche's stock by 4%.CT-388 demonstrated significant weight loss but lacked detailed","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/816101996/image_816101996.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/816101996/image_816101996.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694160-emerging-leaders-roche-viking-therapeutics-obesity-treatment-race","is_publish_highlight":false,"gpt_icon":0},{"id":"2436943953","title":"4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly","url":"https://stock-news.laohu8.com/highlight/detail?id=2436943953","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2436943953?lang=en_us&edition=fundamental","pubTime":"2024-05-17 22:04","pubTimestamp":1715954640,"startTime":"0","endTime":"0","summary":"The obesity market has garnered much interest lately, ever since Novo Nordisk NVO received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant – Eli Lilly’s LLY Zepbound, which received FDA approval last year in November.Lilly and Novo have been registering top- and bottom-line growth, owing to the vastness of the total market size for obesity. The companies even achieved a market cap north of $500 billion. However, these firms have been unable to cope with existing demand and are facing delays in fulfilling orders amid continued supply constraints and product shortages.Wall Street anticipates an even bigger market for obesity drugs. Per research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $100 billion by the end of this decade. This is also evident from the fact that Lilly and Novo are not only investing heavily to optimize their production capacities but have also st","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/exICdiN3pRo85wyejmNeSw--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f505d3082c5c32dd86790426e65a15d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/exICdiN3pRo85wyejmNeSw--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f505d3082c5c32dd86790426e65a15d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-stocks-could-break-novo-140400901.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436690992","title":"Dow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2436690992","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2436690992?lang=en_us&edition=fundamental","pubTime":"2024-05-17 18:43","pubTimestamp":1715942580,"startTime":"0","endTime":"0","summary":"Everyone likes a big round number, and 40,000 sure does sound great. That's the mark the Dow Jones Industrial Average briefly exceeded on Thursday, before losing its gains to close at its second-highest level ever.It's an opportunity to take a step back and ask what it means. And the answer is that it doesn't mean that much, other than that stocks have been going up a lot. The bull run that started toward the end of 2022 is still alive and kicking.However, if you're more interested in where stocks are going than where they've been, earnings from Walmart on Thursday are a good barometer.And the news here was good. Results were better than expected and the world's largest retailer raised guidance for sales, sending the stock to a record high. What's more, they suggested consumer spending is holding up, even after the biggest and fastest increase in interest rates in a generation.That's a good sign for growth, which in turn will help corporate earnings and stocks. But there are storm clou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2436969603","title":"Roche Shows Potential to Grab Slice of Weight-Loss Drug Market -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2436969603","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2436969603?lang=en_us&edition=fundamental","pubTime":"2024-05-17 14:55","pubTimestamp":1715928900,"startTime":"0","endTime":"0","summary":"0655 GMT - Roche's latest weight-loss drug candidate data suggests it has the potential to credibly compete against peers Novo Nordisk and Eli Lilly in the mid to long term, Deutsche Bank analyst Emmanuel Papadakis says in a research note. Roche disclosed its weight-loss drug candidate CT-388 had achieved positive results in an early-stage trial. The phase 1 trial comes amidst a race for a booming weight-loss drug market that includes a class of medicines that has shaken up everything from pharma to snack companies. Deutsche Bank raises its rating on the Swiss drug company's stock to hold from sell. \"After ruminating post-Q1 whether Roche could salvage some sentiment with obesity updates this year, we think it has indeed provided some sufficiently interesting data,\" the analyst says. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2436939151","title":"Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula","url":"https://stock-news.laohu8.com/highlight/detail?id=2436939151","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436939151?lang=en_us&edition=fundamental","pubTime":"2024-05-17 06:36","pubTimestamp":1715898967,"startTime":"0","endTime":"0","summary":"Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021.Nearly all AI-driven drug discovery companies have struggled with overall share pric","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/83803495/image_83803495.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/83803495/image_83803495.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693987-absci-ai-tag-keeping-company-afloat-while-searching-for-right-formula","is_publish_highlight":false,"gpt_icon":0},{"id":"2436389989","title":"Viking falls after Roche’s obesity drug data; RayJay upgrades (update)","url":"https://stock-news.laohu8.com/highlight/detail?id=2436389989","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436389989?lang=en_us&edition=fundamental","pubTime":"2024-05-17 02:37","pubTimestamp":1715884638,"startTime":"0","endTime":"0","summary":"Update 2.37 PM EST: Adds details on Raymond James upgrade Viking Therapeutics (NASDAQ:VKTX) was a notable decliner among anti-obesity drug developers on Thursday after Swiss pharma giant Roche (OTCQX:","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468540296/image_1468540296.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468540296/image_1468540296.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4107654-viking-stock-falls-roche-obesity-data","is_publish_highlight":false,"gpt_icon":0},{"id":"2436936692","title":"Roche: Targeting Mega-Money Obesity Markets After Sharing Stunning Weight Loss Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2436936692","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436936692?lang=en_us&edition=fundamental","pubTime":"2024-05-17 02:00","pubTimestamp":1715882449,"startTime":"0","endTime":"0","summary":"The answer is simple. Lilly and Novo have each developed a class of drug known as a GLP-1 agonist, or \"incretin mimetic,\" as it mimics the action of incretin, a hormone that affects receptors in our brains that control our appetite or how hungry we feel. Lilly's drug, tirzepatide, has been approved to treat type-2 diabetes  under the brand name Mounjaro and to treat obesity under the brand name Zepbound. Novo's drug, semaglutide, is approved to treat T2D under the brand name Ozempic, and obesity, under the brand name Wegovy. In clinical studies, both semaglutide and tirzepatide displayed miraculous weight loss qualities in patients which had previously been regarded as beyond the ability of any drug. As I wrote in a post on the two companies a few weeks ago:  One study of nearly 2,000 patients showed that Ozempic achieved 14.9% weight loss versus 2.4% in the placebo arm, while 84% of patients achieved at least 5% weight loss, versus 31% for placebo. Zepbound's ability to reduce weight ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2055844146/image_2055844146.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2055844146/image_2055844146.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693915-roche-targeting-mega-money-obesity-markets-after-sharing-stunning-weight-loss-data","is_publish_highlight":false,"gpt_icon":0},{"id":"2435605889","title":"Roche's New Weight-Loss Data Shows Lilly Isn't Unbeatable in Obesity -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2435605889","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435605889?lang=en_us&edition=fundamental","pubTime":"2024-05-16 22:08","pubTimestamp":1715868480,"startTime":"0","endTime":"0","summary":"Roche unveiled impressive early-stage results in a small trial of a weight-loss drug called CT-388 that could make the company a serious player in the obesity-drug market in the coming years.The drugmaker said Thursday that after 24 weeks, patients who received CT-388 saw a placebo-adjusted weight loss of 18.8%, on average. While comparisons between trials are difficult, and Roche provided only a bit of data in its press release, analysts said that the numbers might be better than those put up by the current king of the market, Eli Lilly's weight-loss drug Zepbound.In a note on Thursday, William Blair analyst Andy Hsieh wrote that CT-388's data looks strong when compared with earlier studies of Zepbound. \"The rate and magnitude of weight loss exhibited by patients treated with CT-388 appears to be numerically better than those treated with Zepbound,\" he wrote, adding various caveats about the lack of details and the difficulty of cross-trial comparisons.The company said that \"mild to m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435601203","title":"Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2435601203","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435601203?lang=en_us&edition=fundamental","pubTime":"2024-05-16 21:44","pubTimestamp":1715867040,"startTime":"0","endTime":"0","summary":"Roche RHHBY announced positive results from an early-stage study evaluating one of its recently acquired obesity drug candidates, CT-388. Over 24 weeks, patients who received this once-weekly, subcutaneously-injected drug achieved a mean placebo-adjusted weight loss of 18.8%.Per management, the above results were ‘clinically meaningful and statistically significant’ when compared with placebo. Roche also provided an insight into this data. While all patients who received CT-388 achieved more than a weight loss of more than 5%, around 45% of patients lost more than 20% of their body weight.Treatment with CT-388 was also shown to be beneficial to type 2 diabetes  patients. Roche stated that all study participants with a pre-diabetes status at baseline achieved normalized glycemia after 24 weeks of treatment. The glycemic status remained largely unchanged in the placebo-administered study participants.Roche is also evaluating CT-388 in an additional cohort of the phase I study in obese pa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-rhhby-posts-encouraging-phase-134400042.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435673237","title":"Roche obesity therapy leads to ~19% weight loss in Phase 1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2435673237","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435673237?lang=en_us&edition=fundamental","pubTime":"2024-05-16 18:48","pubTimestamp":1715856519,"startTime":"0","endTime":"0","summary":"Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy a","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss","is_publish_highlight":false,"gpt_icon":1},{"id":"2435386621","title":"Roche's Weight-Loss Drug Initial Data Seems Positive But Has Long Path Ahead -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2435386621","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435386621?lang=en_us&edition=fundamental","pubTime":"2024-05-16 16:59","pubTimestamp":1715849940,"startTime":"0","endTime":"0","summary":"0858 GMT - Roche's phase 1 weight loss efficacy results for its injectable dual GLP-1/GLP agonist--which is used to treat obesity and type 2 diabetes--in obese patients are encouraging but have a long road ahead as research & development concerns linger, Jefferies analysts say. \"Questions remain given the highly competitive market before commercial potential can be assessed,\" the analysts says. A key uncertainty is whether the weight-loss curve could reach a plateau for potential efficacy in longer-term studies, Jefferies writes. All test participants achieved more than 5% weight loss at 24 weeks, with 70% having lost over 15%, and 45% over 20% weight loss, noting a normalized blood sugar in all patients. Shares rise 4% to CHF236.50.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435662384","title":"Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2435662384","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435662384?lang=en_us&edition=fundamental","pubTime":"2024-05-16 15:52","pubTimestamp":1715845920,"startTime":"0","endTime":"0","summary":"Roche Holding shares rose after the Swiss pharmaceutical giant said a drug candidate achieved positive results for weight loss in an early-stage clinical trial in adults with obesity.The company joined the race for drugs to treat obesity and diabetes through its purchase of Carmot Therapeutics, seeking a slice of the market that has lifted the fortunes of pharma groups such as Wegovy and Ozempic maker Novo Nordisk and Mounjaro and Zepbound maker Eli Lilly.The obesity drug candidate Roche bought as part of its Carmot deal--known as CT-388--showed positive results in a phase 1 study, by leading to significant weight loss in healthy adults with obesity compared to placebo, the company said Thursday.At 0743 GMT, Roche shares traded 3.8% higher at CHF236.10, but remained down 3.4% since the start of the year.The drug, a once weekly subcutaneous injectable under development for the treatment of obesity and type 2 diabetes, was well tolerated and no new or unexpected safety signals were detec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435633624","title":"Tracking Tweedy Browne Portfolio - Q1 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435633624","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435633624?lang=en_us&edition=fundamental","pubTime":"2024-05-15 18:47","pubTimestamp":1715770041,"startTime":"0","endTime":"0","summary":"Tweedy Browne's 13F portfolio value increased to $2.13B, with 45 holdings.Berkshire Hathaway remains the largest position, followed by Alphabet, Johnson & Johnson, FMC Corporation, and Ionis Pharma.Ne","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953164652/image_953164652.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953164652/image_953164652.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693379-tweedy-browne-portfolio-q1-2024-update","is_publish_highlight":false,"gpt_icon":0},{"id":"1140549718","title":"Wegovy Users Keep Weight off for Four Years, Novo Nordisk Study Says","url":"https://stock-news.laohu8.com/highlight/detail?id=1140549718","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/1140549718?lang=en_us&edition=fundamental","pubTime":"2024-05-15 11:39","pubTimestamp":1715744362,"startTime":"0","endTime":"0","summary":"Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and governments to cover the co","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"gpt_icon":1},{"id":"2435321485","title":"Merck discontinues testing of experimental skin cancer combo therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2435321485","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435321485?lang=en_us&edition=fundamental","pubTime":"2024-05-13 19:58","pubTimestamp":1715601534,"startTime":"0","endTime":"0","summary":"Merck  has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial. KeyVibe-010, a randomized Phase 3 trial, was testing the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and Merck’s blockbuster anti-PD-1 therapy, pembrolizumab , compared to Keytruda alone, as adjuvant treatment for patients with resected high-risk melanoma . The decision to discontinue testing follows an analysis, which showed that it was highly unlikely that the trial could achieve a statistically significant improvement in recurrence-free survival , the study’s primary endpoint. The drugmaker is unblinding the study and recommends that patients receiving the coformulation be offered the option to be treated with Keytruda monotherapy. “A higher rate of discontinuation of all adjuvant therapy by patients in the coformulation arm versus the Keytruda-only arm, primarily due to immune-mediated adverse experiences, rendered it highly unlikely that the tr","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105055-merck-discontinues-testing-of-experimental-skin-cancer-combo-therapy","is_publish_highlight":false,"gpt_icon":0},{"id":"2434829326","title":"Tweedy, Browne 2024 Client Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2434829326","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434829326?lang=en_us&edition=fundamental","pubTime":"2024-05-11 18:50","pubTimestamp":1715424600,"startTime":"0","endTime":"0","summary":"Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy, Browne serves investors in the U.S.The performance of US-based mega-cap technology stocks led to strong market capitalization weighted index performances in 2023.Tweedy managed account portfolios made significant financial progress despite limited exposure to market-leading tech companies.The rotation to value investing continued, with non-US equities remaining undervalued and outperforming their US counterparts.Manoj Madusanka Through chances various, through all vicissitudes, we make our way…","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1843806750/image_1843806750.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1843806750/image_1843806750.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692180-tweedy-browne-2024-client-letter","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roche.com","stockEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":0.0654},{"period":"3month","weight":0.0843},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.22},{"period":"ytd","weight":0.1631}],"description":"Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.","exchange":"OTCQX","name":"Roche Holding Ltd","nameEN":"Roche Holding Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roche Holding Ltd,RHHBY,Roche Holding Ltd股票,Roche Holding Ltd股票老虎,Roche Holding Ltd股票老虎国际,Roche Holding Ltd行情,Roche Holding Ltd股票行情,Roche Holding Ltd股价,Roche Holding Ltd股市,Roche Holding Ltd股票价格,Roche Holding Ltd股票交易,Roche Holding Ltd股票购买,Roche Holding Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction